Avalo Therapeutics (AVTX) CMO Mittie Doyle exercises options and sells 679 shares

Q: What did Avalo Therapeutics (AVTX) CMO Mittie Doyle report in this Form 4?

Mittie Doyle reported exercising 679 stock options at $8.04 and then selling 679 common shares at $20.00 on August 10, 2026, with the activity carried out under a Rule 10b5-1 trading plan .

Q: How many Avalo Therapeutics (AVTX) options did Mittie Doyle exercise and at what price?

Doyle exercised 679 stock options , each with an exercise price of $8.04 per share, resulting in the acquisition of 679 shares of Avalo Therapeutics common stock before a same-day sale of those shares.

Q: At what price did Mittie Doyle sell Avalo Therapeutics (AVTX) shares?

Doyle sold 679 shares of common stock at $20.00 per share on August 10, 2026. This sale followed the exercise of 679 stock options and was executed under a pre-established Rule 10b5-1 trading plan .

Q: How many Avalo Therapeutics (AVTX) stock options does Mittie Doyle retain after this transaction?

After the reported option exercise, Doyle had 114,413 stock options remaining from this award. These options carry an exercise price of $8.04 per share and an expiration date of January 28, 2035 , according to the filing.

Q: What role does Mittie Doyle hold at Avalo Therapeutics (AVTX)?

Mittie Doyle is reported as the Chief Medical Officer of Avalo Therapeutics, Inc. In this capacity, she is an officer of the company and must report transactions in Avalo securities on Form 4 under SEC insider reporting rules.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle reported an option exercise and same-day share sale. On August 10, 2026, Doyle exercised a stock option for 679 shares of common stock at $8.04 per share, then sold 679 shares of common stock at $20.00 per share in a separate transaction. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the option exercise, Doyle had 114,413 stock options remaining under this award.

Insider Trade Summary 10b5-1

Exercise and Sale: 679 shares ($8K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Doyle Mittie

Role Chief Medical Officer

Sold 679 shs ($14K)

Approx. gross sale proceeds $14K

Approx. exercise cost $5K

Approx. pre-tax spread $8K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F2}	679	$0.00	$0.00
Exercise	Common Stock ^F1	679	$8.04	$5K
Sale	Common Stock ^F1	679	$20.00	$14K

Holdings After Transaction: Stock Option (Right to Buy) — 114,413 shares (Direct); Common Stock — 51,776 shares (Direct)

Footnotes (2)

F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
F2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Options exercised: 679 shares Option exercise price: $8.04 per share Shares sold: 679 shares +4 more

7 metrics

Options exercised 679 shares Stock option (right to buy) for common stock exercised on August 10, 2026

Option exercise price $8.04 per share Conversion or exercise price of stock option exercised by Mittie Doyle

Shares sold 679 shares Common stock sold on August 10, 2026 following option exercise

Sale price $20.00 per share Price for the 679 common shares sold in the reported transaction

Remaining options 114,413 shares Total stock options following the reported option exercise

Option expiration January 28, 2035 Expiration date of the stock option from which 679 shares were exercised

10b5-1 plan adoption date November 13, 2025 Date Mittie Doyle adopted the Rule 10b5-1 trading plan used for these trades

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), Exercise or conversion of derivative security, vesting

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title is listed as Stock Option (Right to Buy)"

Exercise or conversion of derivative security financial

"transaction_code_description states Exercise or conversion of derivative security"

vesting financial

"The stock option vests twenty-five percent (25%) on January 28, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What did Avalo Therapeutics (AVTX) CMO Mittie Doyle report in this Form 4?

Mittie Doyle reported exercising 679 stock options at $8.04 and then selling 679 common shares at $20.00 on August 10, 2026, with the activity carried out under a Rule 10b5-1 trading plan.

How many Avalo Therapeutics (AVTX) options did Mittie Doyle exercise and at what price?

Doyle exercised 679 stock options, each with an exercise price of $8.04 per share, resulting in the acquisition of 679 shares of Avalo Therapeutics common stock before a same-day sale of those shares.

At what price did Mittie Doyle sell Avalo Therapeutics (AVTX) shares?

Doyle sold 679 shares of common stock at $20.00 per share on August 10, 2026. This sale followed the exercise of 679 stock options and was executed under a pre-established Rule 10b5-1 trading plan.

How many Avalo Therapeutics (AVTX) stock options does Mittie Doyle retain after this transaction?

After the reported option exercise, Doyle had 114,413 stock options remaining from this award. These options carry an exercise price of $8.04 per share and an expiration date of January 28, 2035, according to the filing.

Was Mittie Doyle’s Avalo Therapeutics (AVTX) trade under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected under a Rule 10b5-1 trading plan adopted by Mittie Doyle on November 13, 2025, indicating the trades were pre-arranged rather than discretionary on the transaction date.

What role does Mittie Doyle hold at Avalo Therapeutics (AVTX)?

Mittie Doyle is reported as the Chief Medical Officer of Avalo Therapeutics, Inc. In this capacity, she is an officer of the company and must report transactions in Avalo securities on Form 4 under SEC insider reporting rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 04:10 PM Accepted by SEC EDGAR 08/12/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/10/2026		M⁽¹⁾		679	A	$8.04	52,455	D
Common Stock	08/10/2026		S⁽¹⁾		679	D	$20	51,776	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.04	08/10/2026		M⁽¹⁾			679	⁽²⁾	01/28/2035	Common Stock	679	$0	114,413	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR